Development Of Minimal Residual Disease (MRD) Analysis In Childhood Acute Lymphoblastic Leukaemia (ALL) By Next Generation Sequencing (NGS)

被引：0

作者：

Williamson, Helen

Mountjoy, Edward

Shihab, Hashem

Bartram, Jack

Hubank, Mike

Goulden, Nicholas

Day, Ian

Roberts, Eileen

Moppett, John

Hancock, Jeremy

机构：

来源：

BLOOD | 2013年 / 122卷 / 21期

关键词：

D O I：

10.1182/blood.V122.21.2569.2569

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2569

引用

页数：2

共 50 条

[31] The kinetics of early response to therapy as determined by PCR-based minimal residual disease (MRD) is highly predictive of outcome in childhood acute lymphoblastic leukaemia (ALL). [J].

Kow-Yin ;

Kham, S ;

Zhao, JB ;

Tan, PL ;

Quah, TC ;

Eng-Juh ;

Yeoh, A .

BLOOD, 2002, 100 (11) :758A-758A

[32] THE PREDICTIVE STRENGTH OF NEXT GENERATION SEQUENCING MINIMAL RESIDUAL DISEASE DETECTION FOR RELAPSE COMPARED WITH CURRENT METHODS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA [J].

Kotrova, M. ;

Muzikova, K. ;

Mejstrikova, E. ;

Novakova, M. ;

Bakardjieva-Mihaylova, V. ;

Fiser, K. ;

Stuchly, J. ;

Pott, C. ;

Bruggemann, M. ;

Stary, J. ;

Trka, J. ;

Fronkova, E. .

HAEMATOLOGICA, 2015, 100 :156-157

[33] Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia [J].

Foroni, L ;

Hoffbrand, AV .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) :71-90

[34] Minimal residual disease in children with acute lymphoblastic leukaemia [J].

Catovsky, D ;

Farahat, N ;

Matutes, E ;

Powles, RL ;

Pinkerton, CR .

LANCET, 1998, 351 (9111) :1287-1287

[35] Next Generation Sequencing (NGS) in acute myeloid leukaemia: a centre experience [J].

Oz Puyan, F. ;

Karaman Gulsaran, S. ;

Umit, E. G. ;

Usta, I. ;

Tastekin, E. ;

Can, N. ;

Kirkizlar, O. ;

Kurt, B. Binboga ;

Demirci, U. ;

Demir, A. M. .

VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) :S115-S115

[36] Minimal residual disease in childhood acute lymphoblastic leukaemia quantified by aspirate and trephine: is the disease multifocal [J].

Sykes, PJ ;

Brisco, MJ ;

Hughes, E ;

Snell, LE ;

Dolman, G ;

Neoh, SH ;

Peng, LM ;

Toogood, I ;

Venables, WN ;

Morley, AA .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) :60-65

[37] Next generation sequencing (NGS) in acute myeloid leukaemia (AML): An update [J].

Haferlach, Torsten .

BONE MARROW TRANSPLANTATION, 2019, 54 :142-142

[38] Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia [J].

Goulden, N ;

Bader, P ;

Van der Velden, V ;

Moppett, J ;

Schilham, M ;

Masden, HO ;

Krejci, O ;

Kreyenberg, H ;

Lankester, A ;

Révész, T ;

Klingebiel, T ;

Van Dongen, J .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) :24-29

[39] Analysis of minimal residual disease predicts relapse in children with standard risk acute lymphoblastic leukaemia (ALL) [J].

Garland, R ;

Goulden, N ;

Knechtli, C ;

Langlands, K ;

Hancock, J ;

Hibbert, E ;

Ferris, V ;

Rowbottom, A ;

Steward, C ;

Potter, M ;

Oakhill, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 :202-202

[40] Minimal residual disease (MRD) status prior to allogeneic BMT for acute lymphoblastic leukaemia (ALL): A critical determinant of successful outcome. [J].

Knechtli, C ;

Hancock, J ;

Harris, E ;

Grandage, V ;

Jones, C ;

Goulden, N ;

Burgess, M ;

Potter, M ;

Cornish, J ;

Pamphilon, D ;

Steward, C ;

Oakhill, A .

BLOOD, 1997, 90 (10) :2430-2430

← 1 2 3 4 5 →